Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
GAITHERSBURG, Md., Nov. 22, 2016 -- Novavax, Inc., (Nasdaq:NVAX) today announced Stanley C Erck, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference.
Conference details are as follows:
Date: Tuesday, November 29, 2016
Time: 3:30 pm U.S. Eastern Time
Location: New York Palace Hotel, New York, New York
Live webcast: novavax.com, “Investors”/ “Events”
A replay of the presentation will also be accessible under the “Investors/Events” section of the Novavax website at novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the Company's website, novavax.com.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Associate Director, Investor Relations [email protected] 240-268-2000 Russo Partners, LLC David Schull Todd Davenport, Ph.D. [email protected] [email protected] 212-845-4271
